Emergent BioSolutions (EBS) Non Operating Income (2011 - 2026)

Emergent BioSolutions' Non Operating Income history runs 16 years deep, the most recent figure standing at $2.9 million for Q1 2026.

• On a quarterly basis, Non Operating Income fell 93.22% year-over-year to $2.9 million in Q1 2026; TTM through Mar 2026 was -$57.2 million, a 257.58% decrease from a year earlier, with the FY2025 full-year figure at -$17.3 million, up 49.42% from the prior year.
• Non Operating Income advanced to $2.9 million in Q1 2026 per EBS's latest filing, from -$22.8 million in the prior quarter.
• Across five years, Non Operating Income topped out at $77.9 million in Q3 2024 and bottomed at -$66.3 million in Q2 2024.
• The 5-year median for Non Operating Income is -$13.0 million (2023), against an average of -$6.0 million.
• Across the five-year window, Non Operating Income soared 495.37% in 2023 and tumbled 255.27% in 2024, its largest moves.
• Year by year, Non Operating Income stood at -$6.1 million in 2022, then sank by 75.41% to -$10.7 million in 2023, then tumbled by 69.16% to -$18.1 million in 2024, then retreated by 25.97% to -$22.8 million in 2025, then jumped by 112.72% to $2.9 million in 2026.
• Per Business Quant, the three latest EBS Non Operating Income figures stand at $2.9 million (Q1 2026), -$22.8 million (Q4 2025), and -$18.9 million (Q3 2025).